News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care L.A. McKeown May 17, 2024
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC Michael O'Riordan March 01, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022